As­traZeneca crit­i­cizes CMS guid­ance in ap­peal over price ne­go­ti­a­tions

More than four months af­ter los­ing a le­gal at­tempt to over­turn parts of the In­fla­tion Re­duc­tion Act’s drug price ne­go­ti­a­tions, As­traZeneca is fir­ing back in …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER